ORG-26576

ORG-26576 is an amplakine compound that was developed by Organon International in collaboration with Pierre Fabre Medicament. It acts as a positive allosteric modulator of the AMPA receptor, which is a type of ionotropic glutamate receptor involved in fast synaptic transmission in the central nervous system.

History

ORG-26576 was first synthesized by Organon International and Pierre Fabre Medicament. The compound was developed as part of a research program aimed at discovering new treatments for neurological disorders and psychiatric disorders.

Mechanism of Action

ORG-26576 works by enhancing the activity of the AMPA receptor. This receptor is a type of ionotropic glutamate receptor that plays a crucial role in fast synaptic transmission in the central nervous system. By modulating the activity of this receptor, ORG-26576 can potentially improve cognitive function and treat various neurological and psychiatric disorders.

Clinical Trials

ORG-26576 has undergone Phase I and Phase II clinical trials. The Phase I trial demonstrated that the compound was well-tolerated in healthy volunteers. The Phase II trial, which was conducted in patients with major depressive disorder, showed that ORG-26576 had a beneficial effect on depressive symptoms. However, further research is needed to confirm these findings and to fully understand the therapeutic potential of this compound.

See Also

• Amplakine
• Organon International
• Pierre Fabre Medicament
• AMPA receptor
• Ionotropic glutamate receptor
• Central nervous system
• Neurological disorders
• Psychiatric disorders
• Major depressive disorder

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia